- Home
- ACXP vs FGEN Comparison
ACXP vs FGEN Comparison
Compare ACXP & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- FGEN
- Stock Information
- Founded
- ACXP 2017
- FGEN 1993
- Country
- ACXP United States
- FGEN United States
- Employees
- ACXP N/A
- FGEN N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- FGEN Health Care
- Exchange
- ACXP Nasdaq
- FGEN Nasdaq
- Market Cap
- ACXP 8.4M
- FGEN 33.5M
- IPO Year
- ACXP 2021
- FGEN 2014
- Fundamental
- Price
- ACXP $0.49
- FGEN $5.61
- Analyst Decision
- ACXP Strong Buy
- FGEN Strong Buy
- Analyst Count
- ACXP 2
- FGEN 1
- Target Price
- ACXP $10.00
- FGEN $250.00
- AVG Volume (30 Days)
- ACXP 18.6M
- FGEN 60.2K
- Earning Date
- ACXP 08-08-2025
- FGEN 08-05-2025
- Dividend Yield
- ACXP N/A
- FGEN N/A
- EPS Growth
- ACXP N/A
- FGEN N/A
- EPS
- ACXP N/A
- FGEN N/A
- Revenue
- ACXP N/A
- FGEN $6,996,000.00
- Revenue This Year
- ACXP N/A
- FGEN N/A
- Revenue Next Year
- ACXP N/A
- FGEN N/A
- P/E Ratio
- ACXP N/A
- FGEN N/A
- Revenue Growth
- ACXP N/A
- FGEN N/A
- 52 Week Low
- ACXP $0.30
- FGEN $4.50
- 52 Week High
- ACXP $3.33
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- ACXP 51.01
- FGEN 39.07
- Support Level
- ACXP $0.46
- FGEN $4.85
- Resistance Level
- ACXP $0.56
- FGEN $5.77
- Average True Range (ATR)
- ACXP 0.10
- FGEN 0.57
- MACD
- ACXP -0.01
- FGEN -0.02
- Stochastic Oscillator
- ACXP 24.27
- FGEN 31.67
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.